Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial

OBJECTIVE: This study evaluated the safety and preliminary efficacy of vorolanib, a novel tyrosine kinase inhibitor, for treatment of patients with advanced solid tumors. METHODS: During dose escalation, patients received increasing doses of oral vorolanib (50−250 mg once daily) in cycles of four we...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Yan, Wang, Jinwan, Ren, Xiubao, Jin, Jie, Mao, Li, Liang, Chris, Ding, Lieming, Yang, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7941683/
https://www.ncbi.nlm.nih.gov/pubmed/33707933
http://dx.doi.org/10.21147/j.issn.1000-9604.2021.01.11

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7941683/
https://www.ncbi.nlm.nih.gov/pubmed/33707933
http://dx.doi.org/10.21147/j.issn.1000-9604.2021.01.11

Ejemplares similares